AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Male Hypogonadism Pipeline Review, H1 2019 - ResearchAndMarkets.com

May 22, 2019

DUBLIN--(BUSINESS WIRE)--May 22, 2019--

The “Male Hypogonadism - Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Male Hypogonadism - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Male Hypogonadism (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Male Hypogonadism (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Male Hypogonadism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 3, 1, 4, 7, 3, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Male Hypogonadism (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Male Hypogonadism - Overview
  3. Male Hypogonadism - Therapeutics Development
  4. Male Hypogonadism - Therapeutics Assessment
  5. Male Hypogonadism - Companies Involved in Therapeutics Development
  6. Male Hypogonadism - Drug Profiles
  7. Male Hypogonadism - Dormant Projects
  8. Male Hypogonadism - Discontinued Products
  9. Male Hypogonadism - Product Development Milestones
  10. Appendix

Companies Mentioned

  • Allergan Plc
  • Clarus Therapeutics Inc
  • Diurnal Group Plc
  • EndoCeutics Inc
  • Ferring International Center SA
  • Lipocine Inc
  • M et P Pharma AG
  • Medlab Clinical Ltd
  • Merck & Co Inc
  • Mereo Biopharma Group Plc
  • TesoRx Pharma LLC
  • Viramal Ltd

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/5hyt7v

View source version on businesswire.com:https://www.businesswire.com/news/home/20190522005701/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Endocrine and Metabolic Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 05/22/2019 01:03 PM/DISC: 05/22/2019 01:03 PM

http://www.businesswire.com/news/home/20190522005701/en

All contents © copyright 2019 The Associated Press.All rights reserved.